CervoMed rises after dementia drug shows promise in mid-stage study

CervoMed

08/10/2025 12:55

** U.S. drug developer CervoMed CRVO.O shares rise 12% to $9.55 in premarket trading

** Co said its experimental drug neflamapimod showed promising results in a mid-stage trial for dementia with Lewy bodies, a common age-related dementia

** Patients taking neflamapimod had significant improvements in memory and daily function versus placebo - CRVO

** CRVO says benefits were most notable in patients unlikely to have Alzheimer's alongside Lewy body dementia

** The results helped CRVO refine plans for a late-stage trial; co expects FDA feedback on its late-stage design by year-end.

** Up to last close, stock up ~265%

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))